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Abstract
Purpose The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of 
debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them.
Methods The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical out-
come of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of 
their routine treatment at 10 Italian Institutions.
Results Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous 
treatments was 3 (range, 0–10) and F and T were administered as ≥ 3rd line in 67 patients. Among the 86 evaluable patients, 
6 (6.9%) achieved CR, 18 (20.7%) PR, and 44 (50.6%) had SD ≥ 24 weeks with an overall CBR of 78.2%. At a median 
follow-up of 33.6 months, mPFS of the entire cohort was 12.9 months (range, 2.47–128.67). No difference was observed 
in mPFS between patients treated after progression or as maintenance therapy (mPFS 12.9 and 13.9 months in 64 and 23 
patients, respectively), neither considering the number of previous treatment lines (≤ 3 or < 3).
Conclusion The combination of F and T was active in this cohort at poor prognosis and deserves further investigations pos-
sibly in combination with pertuzumab in patients with high ER expression.
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Introduction
Gene expression studies have clearly demonstrated in 
recent years that HER2-positive (HER2 +) breast cancer 
is a heterogeneous disease [1]. Approximately, 50% of 
HER2 + tumors are hormone receptor positive (HR +) at 
immunohistochemistry (IHC) [2]
However, only one half of HER2 + tumors at IHC cor-
respond to the HER2-enriched subtype as defined by gene 
expression profiling, and within the latter subtype signifi-
cant molecular differences were observed according to the 
HR expression [3]
However, these immunohistochemical and molecular 
differences do not translate in different therapeutic strate-
gies for treatment of HR + /HER2 + tumors which routinely 
include chemotherapy and anti-HER2 agents [4]. Preclini-
cal evidence suggesting that HER2 overexpression was 
associated with endocrine resistance [5], further confirmed 
by the poor results of earlier studies investigating a chem-
otherapy-free regimen in advanced HR + /HER2 + tumors 
[6, 7], supported an unique treatment strategy including 
chemotherapy plus anti-HER2 therapy irrespective of HR 
status [5]. However, results from neoadjuvant trials and 
from the advanced setting clearly indicated less sensitive-
ness of luminal HER2 + tumors to this approach probably 
due to a bidirectional cross-talk between the two driver 
receptors, estrogen and HER2 [8–11]. Co-targeting of both 
receptors appears thus an attractive strategy to overcome 
the resistance due to this cross-talk [12].
The availability of fulvestrant which internalizes ER 
after binding, leading to a more complete abolishment of 
the estrogen signaling with respect to aromatase inhibitors, 
might represent an attractive targeted partner for a full HR/
HER2 blockade [13]. A synergistic effect between fulves-
trant and trastuzumab in inhibiting growth in cell lines and 
xenografts has been shown, but only a few in vivo data are 
available on the combination [14].
In the present retrospective observational study 
we report a real-world series of patients with HR + /
HER2 + advanced breast cancer (ABC) treated with the 
combination of fulvestrant and trastuzumab and analyze 
possible predictive factors of its effectiveness.
Patients and methods
The HERMIONE 9 is an observational retrospective mul-
ticentric study which aimed to describe the clinical out-
come of patients with HR + /HER2 + ABC who received 
the combination of fulvestrant and trastuzumab as part of 
their routine treatment at 10 Italian Institutions participat-
ing to the HERMIONE platform.
Eligible patients were pre- and postmenopausal women 
aged ≥ 18 years diagnosed with HR + (defined as ER and/
or PgR ≥ 10%) and HER2 + (defined as IHC 3 + or FISH or 
CISH or SISH positive) inoperable locally advanced and/or 
metastatic breast cancer. Premenopausal patients received 
concomitant ovarian suppression with GnRH analogues. 
Fulvestrant + trastuzumab were administered as any line 
of treatment. Fulvestrant was administered 500 mg i.m. 
q28 days with loading dose after 14 days; trastuzumab was 
administered q21 days either as 8 mg/kg loading dose and 
then 6 mg/kg i.v. infusion or 600 mg s.c., according to the 
internal institutional guidelines.
Patient medical charts were reviewed and tumor response 
was assessed. Since this is a retrospective study response 
could not be evaluated according to RECIST 1.1 criteria in 
all patients, but CT scans and other imaging were reviewed 
in order to comply with RECIST criteria whenever possible.
Information on age at diagnosis, menopausal status, pre-
vious adjuvant therapies, number of previous therapies for 
metastatic disease, number and response to previous thera-
pies for metastatic disease, pathological features of primary 
and metastatic tumor if available, sites of metastatic disease, 
best response, and disease progression if occurred, and last 
follow-up visit were collected.
This study was approved by the institutional ethical com-
mittee of the coordinating center (Humanitas Research Hos-
pital) and of all the other participating Institutions and was 
conducted in compliance with Helsinki Declaration.
Statistical analysis
Clinical data were summarized as frequencies and propor-
tions or as medians and range. To assess the tumor hetero-
geneity, we calculated the agreement in the tumor biologi-
cal profile between primary and metastatic sites in terms of 
ER, PgR, and HER2 expression using Cohen’s K statistics. 
Response to treatment was classified as complete response 
(CR), partial response (PR), stable disease (SD), or pro-
gressive disease (PD) according to the Response Evalua-
tion Criteria in Solid Tumors (RECIST) criteria version 1.1 
whenever possible. Clinical Benefit Rate (CBR) was defined 
as the percentage of patients who achieved CR, PR, and 
SD ≥ 24 weeks. Survival curves were estimated using the 
Kaplan–Meier method. Progression-Free Survival (PFS) was 
defined as the time from the first day of fulvestrant + trastu-
zumab until disease progression, as shown by radiological 
or clinical examination, or death from any cause. Patients 
without any evidence of progressive disease were censored 
at the date of their last follow-up. PFS curves were analyzed 
according to disease status at fulvestrant + trastuzumab start, 
early versus later fulvestrant + trastuzumab line of treatment, 
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the type of previous therapy, and HR status. Differences 
among subgroups were evaluated using the log-rank test.
Statistical significance was set at 0.05. Analyses were per-
formed with the STATA software package, version 15 and 
with STATISTICA version 7, StatSoft, Inc.
Results
From August 2005 to March 2021 a total of 87 patients were 
treated with the combination of fulvestrant + trastuzumab at 
the 10 participating Institutions.
Median age was 63 years (range, 35–87). Clinical patho-
logical patients’ characteristics are reported in Table 1. 
Thirty-one percent (27/87) of the patients were diagnosed 
with de novo metastatic breast cancer; in recurrent ABC 
(60/87, 69%), median time to metastatic disease was 
57.1 months (range, 7.0–330.5).
A biopsy of metastatic site was available in 48 out of 
87 patients (45.9%); biological characteristics of metasta-
ses were concordant with those of primary tumors except 
for PgR expression which was significantly lower (p = 0.02) 
As a consequence, 59 patients (67.8%) had triple-positive 
tumors as determined in the primary tumor while in meta-
static biopsies only 22 /45 (49%) metastatic tumors were 
triple positive.
The median number of previous treatments (both chemo-
therapy ± trastuzumab and endocrine therapy + trastuzumab) 
for advanced disease was 3 (range, 0–10). Fulvestrant + tras-
tuzumab were administered as ≥ 3 line in 67 patients. All 
patients had received trastuzumab previously while only 
19% of patients had not received prior endocrine therapy 
for ABC.
Twenty-three patients started fulvestrant + trastuzumab 
as maintenance treatment while 64 patients had progressed 
upon the previous regimen (20 patients after endocrine 
therapy + trastuzumab, 22 after anti-HER2 agents + chemo-
therapy, and 20 after chemotherapy).
The median duration of fulvestrant + trastuzumab treat-
ment was 11.5 months (range, 2.03–128.67). Trastuzumab 
was administered i.v. (57/87, 65.52%), or s.c. (15/87, 
17.24%), or both (11/87, 12.64%); the data were not avail-
able in 4 cases.
Eight-six patients were evaluable for response: 6 
patients achieved CR (6.9%), 18 patients (20.7%) PR, and 
51 patients (58.6%) SD—of whom 44 patients (50.6%) had 
SD ≥ 24 weeks. Overall, the CBR was 78.2%. At a median 
follow-up of 33.6 months (range, 2.47–139.27), mPFS of the 
entire cohort was 12.9 months (range, 2.47–128.67; Fig. 1). 
A shorter time to progression (TTP) was observed during the 
treatment immediately preceding fulvestrant + trastuzumab 
(7.62 months, range, 2.0–98.9). No statistically significant 
difference was observed in mPFS in patients treated after 
Table 1  Baseline patient and disease characteristics
Median age, years (range) 63 (35–87)
De novo mBC, n (%) 27 (31.03)
















HR status, n (%)
 ER + /PgR + 59 (67.81)
 ER + /PgR− 24 (27.59)
 ER −/PgR + 0 (0.0)
 ER −/PgR − 4 (4.60)
Median (range) %ER + staining 70 (20–100)
Median (range) %PgR + staining 50 (10–80)
























 ≥ 3 29 (33.33)
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progression to a previous line or as maintenance (mPFS 
12.9 and 13.9 months, respectively; p = 0.67), neither con-
sidering the number of previous treatment lines (≤ 3 or < 3) 
(p = 0.34), the type of previous therapy (chemotherapy or 
endocrine therapy), or triple positive vs single HR expres-
sion overall (p = 0.22).
Discussion
In the era of tailored treatments the most appropriate therapy 
of HR + /HER2 + BC is a matter of debate. While showing 
less responsiveness to the combination of chemotherapy 
plus anti-HER2 agents as compared to the HR negative 
counterpart, results with the combination of anti-HER2 
agents and non-steroidal aromatase inhibitors (NSAI) 
have been quite disappointing with a mPFS not exceeding 
4.8 months with trastuzumab and anastrozole and 8.2 months 
with lapatinib and letrozole as first-line treatment [6, 7]. The 
recently updated ALTERNATIVE trial, which investigated 
the addition of lapatinib, trastuzumab, or both agents to a 
NSAI, showed a significant improvement in mPFS for the 
double HER2 blockade vs trastuzumab plus NSAI (11 vs 
5.6 months) [15]. On the other hand the PERTAIN trial 
reported a mPFS of 21.7 months in the arm with the dou-
ble HER2 blockade with pertuzumab and trastuzumab plus 
a NSAI, which was not only significantly higher than that 
reported by the trastuzumab plus NSAI combination but, 
more importantly, was similar to that reported in patients 
who had received chemotherapy before endocrine therapy 
(mPFS = 18.9 months) [16]. The relative small number of 
patients (54) and the non-randomized assignment to the 
chemotherapy/no chemotherapy arms leading to a smaller 
proportion of patients with poor prognostic features in the 
latter arm, do not allow to qualify the chemotherapy-free 
combination as a standard first-line treatment for HR + /
HER2 + ABC, but clearly represents a strong rationale for 
further studies to identify which patients may be spared 
unnecessary chemotherapy [16].
Fulvestrant was proven superior to NSAI in patients 
with HR + /HER2—ABC [17] and has been considered 
as favorite anti-ER partner in combination with other tar-
geted therapies in HR + /HER2 + breast cancer (Na-PHer2, 
MonarcHER), despite the lack of clinical data of the activ-
ity of this combination [18, 19]. Fulvestrant monotherapy 
showed an encouraging activity in a retrospective study in 
102 pretreated patients with HR + /HER2 + ABC with a CBR 
of 42% and a median duration of treatment of 8.1 months, 
which raised to 14.5 months in patients achieving clinical 
benefit. Among them only 5 patients had received concur-
rent trastuzumab [20]. Bartsch et al. reported outcomes of 
112 patients with HR + tumors treated with Fulvestrant 20 
of whom had HR + /HER2 + tumors and HER2 status did not 
predict treatment efficacy [21]. Rusz et al. reported a durable 
benefit (12, 25, and 28 months) with Fulvestrant monother-
apy in 3 pretreated patients with triple-positive ABC [22]. 
The SystHER, an observational prospective registry study 
reporting tumor characteristics, treatment patterns, and out-
come of patients with HER2 + ABC treated in the USA from 
2012 to 2016, included 46 patients who received Fulvestrant 
but no further information on the setting and outcome is 
available yet [23].
To our knowledge this is the first report of the combina-
tion of fulvestrant + trastuzumab in a clinically relevant num-
ber of patients. We observed a mPFS of 12.9 months and a 
CBR of 78% which favorably compare with those previously 
reported by the combination of a NSAI and trastuzumab 
HR hormone receptor, ER estrogen receptor, PgR progesterone recep-
tor, CT chemotherapy, ET endocrine therapy, F fulvestrant, T trastu-
zumab
Table 1  (continued)
Median age, years (range) 63 (35–87)





Last treatment before F + T, n (%)
 CT + trastuzumab 23 (26.43)
 ET + trastuzumab 20 (22.99)
 T DM1 8 (9.20)
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Time (months)
Progression-Free Survival
Fig. 1  Progression-free survival in the overall population
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even when administered in earlier lines [6, 7, 15, 16]. Only 
the addition of pertuzumab gained a superior mPFS in the 
PERTAIN study [16]. As expected, our results favorably 
compare also with those obtained with single agent Fulves-
trant, particularly in terms of CBR [20–22].
Remarkably, 77% of our patients had been treated with ≥ 3 
previous therapies for metastatic disease, 73% started ful-
vestrant + trastuzumab after progression to a previous regi-
men, and more than 50% had visceral disease. The short 
TTP (7.5 months) observed with the treatment preceding 
the fulvestrant + trastuzumab combination confirms that our 
unselected population represented a really poor prognosis 
cohort.
Fulvestrant was administered as first-line endocrine ther-
apy only in 19% of patients but its activity did not seem to be 
affected by prior endocrine resistance since the patients (20) 
who had progressed on endocrine therapy + trastuzumab had 
a mPFS of 14.26 months (4.37–119.93), thus maintaining 
responsiveness to a different endocrine manipulation. On the 
other hand, also patients progressing after a chemotherapy 
containing regimen experienced an mPFS of 12.73 months 
(range 3.07–59.57); in both cohorts the mPFS was signifi-
cantly longer than the TTP obtained with the preceding ther-
apy underlining the activity of the combination irrespective 
of prior treatments.
Despite the benefit of endocrine maintenance therapy 
has not been formally investigated in a randomized trial, 
evidence from PERTAIN and real-world reports support 
the efficacy of a sustained blockade of the ER signaling in 
HR + /HER2 + breast cancer [25, 26]. Our results reporting a 
mPFS of 13.9 months in patients who received maintenance 
fulvestrant are in line with these reports.
Interestingly, in our study triple-positive tumors did not 
fare better than single HR-positive tumors. Triple-positive 
breast cancer, which accounts for 5–10% of all breast can-
cers, might represent a distinct subtype among luminal 
HER2 breast cancer with more exquisite endocrine sensi-
tiveness. [27]. However, triple-positive breast cancer has 
been described as a heterogeneous population. A genomic 
analysis of 5 cohorts of triple-positive breast cancer showed 
lower levels of HER2 mRNA and protein expression than 
ER and PgR positive/HER2 + breast cancers. More than 40% 
of triple-positive breast cancers were classified as the lumi-
nal A intrinsic subtype, with an even lower HER2 expres-
sion level and were associated with a better prognosis and a 
reduced benefit from trastuzumab [28]
In a large retrospective series of 872 patients Vici et al. 
showed a significant interaction between HR expression and 
trastuzumab benefit since patients with triple positive tumors 
and HR > 50% gained a modest benefit from adjuvant anti-
Her2 treatment [29]. In our series ER status maintained a 
predictive role, while PgR was not associated with response. 
The loss of PgR, which may be also attributable to previous 
endocrine treatment, apparently did not represent a feature of 
endocrine resistance, as suggested by its lower expression in 
metastatic sites without affecting treatment efficacy.
A reduced benefit of the combination of chemotherapy 
and trastuzumab in the adjuvant setting was shown in a ret-
rospective analysis of the National Cancer Database among 
37777 stage I luminal HER2 + breast cancer. A large propor-
tion had received only the combination of endocrine therapy 
and trastuzumab and had an improved overall survival as 
compared with patients who were treated with chemotherapy 
and trastuzumab [30].
Fulvestrant has been chosen as preferred endocrine part-
ner in combination with anti-HER2 agents and CDK4/6 
inhibitors either in the early and advanced setting [18, 19], 
In the phase II Na-PHER2 study the combination of pertu-
zumab, trastuzumab, fulvestrant, and palbociclib achieved 
an objective response and a pathological complete response 
in 97 and 27% of patients with large HR + /HER2 + tumors, 
respectively [18].
The MonarcHER study randomized the combination of 
fulvestrant, trastuzumab and abemaciclib vs trastuzumab, 
and abemaciclib vs trastuzumab plus chemotherapy in heav-
ily pretreated HR + /HER2 + ABC [19]. The triple targeted 
regimen resulted in a mPFS of 8.3 months significantly 
higher than that obtained with chemotherapy, suggesting a 
benefit of the addition of the blockade of the CDK4/6 path-
way. The lack of an arm containing fulvestrant and trastu-
zumab has represented the major criticism to these results 
since this did not allow to evaluate the net benefit of the 
CDK4/6 inhibitor.
These results, along with other indirect evidence, suggest 
that at least a proportion of luminal HER2 + breast cancer 
may experience a favorable outcome without chemotherapy.
We are aware of several limitations of our real-world 
study as compared with prospective trials. First of all the 
retrospective design which may have not allowed to meet 
with a strict application of RECIST 1.1 criteria in all the 
patients. In addition the majority of our patients had not 
received pertuzumab in earlier lines and this may have led 
to the inclusion of a relatively less resistant cohort. Finally, 
given the multicentric design, the sequence of treatments 
varied among the different Hospitals and might have inter-
fered with the results obtained especially with the definition 
of predictive factors of efficacy.
Despite these limitations, our results provide a piece 
of evidence in the refinement of the optimal treatment of 
HR + /HER2 + breast cancer. Our results suggest that the 
combination of fulvestrant and trastuzumab is active and 
may deserve further investigations, possibly in combination 
with pertuzumab and in patients with high ER expression. 
Patients with de novo HR + /HER2 + ABC, who represent 
30% to 50% of patients receiving first-line treatment, gen-
erally experience better outcome as compared with those 
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with recurrent ABC [24]. For instance, it would be inter-
esting to test this combination ± CDK4/6 inhibitors vs the 
chemotherapy containing triplet in this population at better 
prognosis to understand whether the algorithm of treatment 
of HER2 + breast cancer may be tailored according to the 
HR status.
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